Home Cart Sign in  
Chemical Structure| 1391934-98-7 Chemical Structure| 1391934-98-7

Structure of FIDAS-5
CAS No.: 1391934-98-7

Chemical Structure| 1391934-98-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities[1].

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FIDAS-5

CAS No. :1391934-98-7
Formula : C15H13ClFN
M.W : 261.72
SMILES Code : CNC1=CC=C(/C=C/C2=C(F)C=CC=C2Cl)C=C1
MDL No. :MFCD32671894
InChI Key :KXVXICBOMOGFMH-JXMROGBWSA-N
Pubchem ID :57521314

Safety of FIDAS-5

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U251-MG cells 10 μM 10 days To evaluate the effect of FIDAS-5 on tumorsphere formation, results showed that FIDAS-5 significantly reduced the number and diameter of tumorspheres and decreased the expression levels of SOX2 and OCT4. Life Med. 2023 Nov 23;2(6):lnad048
U87-MG cells 10 μM 10 days To evaluate the effect of FIDAS-5 on tumorsphere formation, results showed that FIDAS-5 significantly reduced the number and diameter of tumorspheres and decreased the expression levels of SOX2 and OCT4. Life Med. 2023 Nov 23;2(6):lnad048
OPM2 cells 250 nM 4 days Inhibited cell proliferation, reduced BrdU incorporation, and caused G0/G1 and G2 phase cell cycle arrest Haematologica. 2024 Jan 1;109(1):256-271
JJN3 cells 250 nM 4 days Inhibited cell proliferation, reduced BrdU incorporation, and caused G0/G1 and G2 phase cell cycle arrest Haematologica. 2024 Jan 1;109(1):256-271
Hep3B cells 1 μM 72 hours Induced cell cycle arrest and DNA damage, leading to cellular senescence Nat Cancer. 2024 Jan;5(1):131-146
Huh7 cells 5 μM 72 hours Induced cell cycle arrest and DNA damage, leading to cellular senescence Nat Cancer. 2024 Jan;5(1):131-146
mouse HL-1 cardiomyocytes 5 μM 24-30 hours Inhibited MAT2A activity, significantly suppressing ferroptosis induced by cystine deprivation Nat Commun. 2024 Oct 17;15(1):8971
human OS-RC-2 renal carcinoma cells 5 μM 14-18 hours Inhibited MAT2A activity, significantly suppressing ferroptosis induced by cystine deprivation Nat Commun. 2024 Oct 17;15(1):8971
human HT1080 fibrosarcoma cells 5 μM 10-14 hours Inhibited MAT2A activity, significantly suppressing ferroptosis induced by cystine deprivation Nat Commun. 2024 Oct 17;15(1):8971
mouse embryonic fibroblast (MEF) cells 5 μM 8-12 hours Inhibited MAT2A activity, significantly suppressing ferroptosis induced by cystine deprivation or blockage of cystine uptake Nat Commun. 2024 Oct 17;15(1):8971

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/KaLwRij mice 5TGM1 model Intraperitoneal injection 20 mg/kg Three times a week for 28 days Significantly reduced tumor burden, decreased percentage of eGFP-positive cells and bone marrow plasmacytosis Haematologica. 2024 Jan 1;109(1):256-271
Nude mice Huh7 and Hep3B xenograft models Intraperitoneal injection 10 mg/kg Once daily for 7 days Inhibited tumor growth and induced tumor cell senescence Nat Cancer. 2024 Jan;5(1):131-146
Nude mice OS-RC-2 tumor xenograft model Intragastrically 20 mg/kg Every 2 days for 12 days Inhibited MAT2A activity, attenuating IKE-induced tumor growth suppression Nat Commun. 2024 Oct 17;15(1):8971
NSG mice Orthotopic GBM xenografts Intraperitoneal injection 40 mg/kg Daily treatment To evaluate the effect of FIDAS-5 on tumor growth, results showed that FIDAS-5 significantly inhibited the growth of xenografts and conferred a significant survival benefit relative to the vehicle control. Life Med. 2023 Nov 23;2(6):lnad048

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.82mL

0.76mL

0.38mL

19.10mL

3.82mL

1.91mL

38.21mL

7.64mL

3.82mL

References

 

Historical Records

Categories